Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia/Lymphoma
  • Prolymphocytic Leukemia
  • Lymphoplasmacytic Lymphoma
  • Mantle Cell Lymphoma
  • Acute Myeloid Leukemia
  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Relapsed Small Lymphocytic Lymphoma
  • Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
  • Bone Marrow Failure Syndromes
  • Burkitt's Lymphoma
  • Chronic Myelogenous Leukemia
  • Relapsed T-Cell Lymphoma
  • Myeloproliferative Neoplasms/Myelofibrosis
  • Relapsed Chronic Lymphocytic Leukemia
  • Follicular Lymphoma
  • Natural Killer Cell Malignancies
  • Hodgkin Lymphoma
  • Large Cell Lymphoma
  • MRD Positive Leukemia
  • Leukemia or MDS in Aplasia
  • Marginal Zone B Cell Lymphoma
  • Myelodysplastic Syndrome
  • Plasma Cell Leukemia
Type
Interventional
Phase
Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Younger than 75 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT02722668
Collaborators
Not Provided
Investigators
Principal Investigator: Claudio Brunstein, MD, PhD University of Minnesota